無料プレビュー

Liquidia Corporation (LQDA) · NASDAQ Capital Market

プロフィール

Liquidia Corp is a biopharmaceutical company developing treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company markets YUTREPIA (treprostinil) inhalation powder, approved in May 2025, and shares profits from Sandoz's generic Treprostinil Injection through a promotion agreement. It also develops L606, an inhaled liposomal treprostinil formulation, leveraging its proprietary PRINT particle-engineering platform. The company operates through two subsidiaries and employs a targeted sales force in the United States.

主要指標

株価: $28.02 (+5.02%)
時価総額: 25億ドル
PER（今期予想）: 11.3
PBR: 12.8
配当利回り: —
52週レンジ: $21.94 – $93.61
業種: Healthcare / Medical - Pharmaceuticals
上場: NASDAQ Capital Market
構成銘柄: —

比較会社: RPRX Royalty Pharma plc、UTHR United Therapeutics Corporation、INSM Insmed Incorporated、CORT Corcept Therapeutics Incorporated、WBA Walgreens Boots Alliance, Inc.、KNSA Kiniksa Pharmaceuticals International, plc、VCRE Vicore Pharma Holding AB、PBH Prestige Consumer Healthcare Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-02 · 更新: 2026-10-09